Influences of Ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure  

作　　者：Peter JIRAK Dzeneta FEJZIC Vera PAAR Bernhard WERNLY Rudin PISTULLI Ilonka ROHM Christian JUNG Uta C HOPPE P Christian SCHULZE Michael LICHTENAUER Atilla YILMAZ Daniel KRETZSCHMAR 

机构地区：[1]Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Austria [2]Department of Internal Medicine I, Division of Cardiology, Angiology, Pneumology and Intensive Medical Care, University Hospital Jena, Friedrich Schiller University Jena, Germany [3]Division of Cardiology, Pulmonology, and Vascular Medicine, Medical Faculty, University of Duesseldorf,Germany [4]Clinic of Internal Medicine II, Elisabeth-Hospital Schmalkalden, Germany

出　　处：《Acta Pharmacologica Sinica》2018年第7期1189-1196,共8页中国药理学报（英文版）

摘　　要：Chronic heart failure （CHF） represents a major cause of hospitalization and death. Recent evidence shows that novel biomarkers such as soluble suppression of tumorigenicity （sST2）, growth-differentiation factor-15 （GDF-15）, soluble urokinase plasminogen activator receptor （suPAR） and heart-type fatty acid binding protein （H-FABP） are correlated with inflammatory and ischemic responses in CHF patients. In this study we examined the effects of Ivabradine that inhibited the hyperpolarization-activated cyclic nucleotide-gated channel （HCN channel, also called funny current If）, thereby leading to selective heart rate reduction and improved myocardial oxygen supply on the cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in 50 CHF patients at the University Hospital of Jena. Patients were divided into three groups based on the etiology of CHF： dilated cardiomyopathy （DCM, n=20）, ischemic cardiomyopathy （ICM, n=20） and hypertensive cardiomyopathy （HCM, n=10）. The patients were administered Ivabradine （5 mg, bid for 3 months, and 7.5 mg bid for further 3 months）. Analyses of cardiovascular biomarkers were performed at baseline as well as at 3- and 6-month follow- ups. At 6-month follow-up, GDF-15 levels were significantly reduced compared to baseline levels （P=0.02i5）, indicating a reduction in the progress of cardiac remodeling. H-FABP concentration was significantly lower in DCM patients compared to ICM （1.89 vs 3.24 μg=mL） and HCM patients （1.89 vs 3.80 μg/mL）, and decreased over the 6-month follow-up （P=0.0151）. suPAR median levels remained elevated, implying major ongoing inflammatory processes. As shown by significant decreases in GDF-15 and H-FABP levels, a reduction in ventricular remodeling and sub-clinical ischemia could be assumed. However, markers of hemodynamic stress （sST2） and inflammation （suPAR） showed no change or progression after 6 months of Ivabradine treatment in CHF patients. Further studies are necessary to validate the clinical Chronic heart failure （CHF） represents a major cause of hospitalization and death. Recent evidence shows that novel biomarkers such as soluble suppression of tumorigenicity （sST2）, growth-differentiation factor-15 （GDF-15）, soluble urokinase plasminogen activator receptor （suPAR） and heart-type fatty acid binding protein （H-FABP） are correlated with inflammatory and ischemic responses in CHF patients. In this study we examined the effects of Ivabradine that inhibited the hyperpolarization-activated cyclic nucleotide-gated channel （HCN channel, also called funny current If）, thereby leading to selective heart rate reduction and improved myocardial oxygen supply on the cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in 50 CHF patients at the University Hospital of Jena. Patients were divided into three groups based on the etiology of CHF： dilated cardiomyopathy （DCM, n=20）, ischemic cardiomyopathy （ICM, n=20） and hypertensive cardiomyopathy （HCM, n=10）. The patients were administered Ivabradine （5 mg, bid for 3 months, and 7.5 mg bid for further 3 months）. Analyses of cardiovascular biomarkers were performed at baseline as well as at 3- and 6-month follow- ups. At 6-month follow-up, GDF-15 levels were significantly reduced compared to baseline levels （P=0.02i5）, indicating a reduction in the progress of cardiac remodeling. H-FABP concentration was significantly lower in DCM patients compared to ICM （1.89 vs 3.24 μg=mL） and HCM patients （1.89 vs 3.80 μg/mL）, and decreased over the 6-month follow-up （P=0.0151）. suPAR median levels remained elevated, implying major ongoing inflammatory processes. As shown by significant decreases in GDF-15 and H-FABP levels, a reduction in ventricular remodeling and sub-clinical ischemia could be assumed. However, markers of hemodynamic stress （sST2） and inflammation （suPAR） showed no change or progression after 6 months of Ivabradine treatment in CHF patients. Further studies are necessary to validate the clinical

关 键 词：heart failure CARDIOMYOPATHY IVABRADINE heart rate biomarker sST2 GDF-15 SUPAR H-FABP 

分 类 号：Q463[生物学—生理学] S813.14[农业科学—畜牧学]